.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Updates in the Treatment of HR+/HER2- Breast Cancer

EP. 1: Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer

December 24th 2024

Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use of tools like RSClin N+, and the evolving role of CDK4/6 inhibitors and adjuvant therapies. They also address challenges in risk assessment and the integration of newer treatment strategies, such as CDK4/6 inhibitors and PARP inhibitors in the early-stage setting.